214 related articles for article (PubMed ID: 33098213)
1. Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis.
Dmochowski RR; Thai S; Iglay K; Enemchukwu E; Tee S; Varano S; Girman C; Radican L; Mudd PN; Poole C
Neurourol Urodyn; 2021 Jan; 40(1):28-37. PubMed ID: 33098213
[TBL] [Abstract][Full Text] [Related]
2. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome.
Taylor-Rowan M; Edwards S; Noel-Storr AH; McCleery J; Myint PK; Soiza R; Stewart C; Loke YK; Quinn TJ
Cochrane Database Syst Rev; 2021 May; 5(5):CD013540. PubMed ID: 34097766
[TBL] [Abstract][Full Text] [Related]
3. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.
Gray SL; Anderson ML; Dublin S; Hanlon JT; Hubbard R; Walker R; Yu O; Crane PK; Larson EB
JAMA Intern Med; 2015 Mar; 175(3):401-7. PubMed ID: 25621434
[TBL] [Abstract][Full Text] [Related]
4. SUFU white paper on overactive bladder anticholinergic medications and dementia risk.
Zillioux J; Welk B; Suskind AM; Gormley EA; Goldman HB
Neurourol Urodyn; 2022 Nov; 41(8):1928-1933. PubMed ID: 36066046
[TBL] [Abstract][Full Text] [Related]
5. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis.
Pieper NT; Grossi CM; Chan WY; Loke YK; Savva GM; Haroulis C; Steel N; Fox C; Maidment ID; Arthur AJ; Myint PK; Smith TO; Robinson L; Matthews FE; Brayne C; Richardson K
Age Ageing; 2020 Oct; 49(6):939-947. PubMed ID: 32603415
[TBL] [Abstract][Full Text] [Related]
6. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
Rai BP; Cody JD; Alhasso A; Stewart L
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
[TBL] [Abstract][Full Text] [Related]
7. Anticholinergic drugs and risk of dementia: Time for action?
Bell B; Avery A; Bishara D; Coupland C; Ashcroft D; Orrell M
Pharmacol Res Perspect; 2021 May; 9(3):e00793. PubMed ID: 34087056
[TBL] [Abstract][Full Text] [Related]
8. The cognitive safety of antimuscarinics in the treatment of overactive bladder.
Araklitis G; Robinson D
Expert Opin Drug Saf; 2020 Oct; 19(10):1303-1313. PubMed ID: 32857638
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Am J Obstet Gynecol; 2023 Sep; 229(3):316.e1-316.e7. PubMed ID: 37244459
[TBL] [Abstract][Full Text] [Related]
10. Anticholinergic medications and risk of dementia in older adults: Where are we now?
Chatterjee S; Talwar A; Aparasu RR
Expert Opin Drug Saf; 2020 Oct; 19(10):1251-1267. PubMed ID: 32797761
[TBL] [Abstract][Full Text] [Related]
11. Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.
Lozano-Ortega G; Walker DR; Johnston K; Mickle A; Harrigan S; Rogula B; Kristy RM; Hairston JC; Schermer CR
Drugs Aging; 2020 Nov; 37(11):801-816. PubMed ID: 32960422
[TBL] [Abstract][Full Text] [Related]
12. Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):69-71. PubMed ID: 33497068
[TBL] [Abstract][Full Text] [Related]
13. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
15. Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study.
Grossi CM; Richardson K; Fox C; Maidment I; Steel N; Loke YK; Arthur A; Myint PK; Campbell N; Boustani M; Robinson L; Brayne C; Matthews FE; Savva GM
BMC Geriatr; 2019 Oct; 19(1):276. PubMed ID: 31638906
[TBL] [Abstract][Full Text] [Related]
16. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale.
Suh Y; Ah YM; Han E; Jun K; Hwang S; Choi KH; Lee JY
BMC Geriatr; 2020 Jul; 20(1):265. PubMed ID: 32727410
[TBL] [Abstract][Full Text] [Related]
17. AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
This document was developed by the American Urogynecologic Society (AUGS) Guidelines Committee with the assistance of Tonya N. Thomas, MD, and Mark D. Walters, MD. This document reflects clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Its content is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. The ultimate judgment regarding any specific procedure or treatment is to be made by the physician and patient in light of all circumstances presented by the patient.
Female Pelvic Med Reconstr Surg; 2017; 23(3):177-178. PubMed ID: 28441276
[TBL] [Abstract][Full Text] [Related]
18. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.
Carrière I; Fourrier-Reglat A; Dartigues JF; Rouaud O; Pasquier F; Ritchie K; Ancelin ML
Arch Intern Med; 2009 Jul; 169(14):1317-24. PubMed ID: 19636034
[TBL] [Abstract][Full Text] [Related]
19. Anticholinergics and clinical outcomes amongst people with pre-existing dementia: A systematic review.
Wang K; Alan J; Page AT; Dimopoulos E; Etherton-Beer C
Maturitas; 2021 Sep; 151():1-14. PubMed ID: 34446273
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
